Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 17;7(4):53.
doi: 10.3390/jcdd7040053.

A Bioengineered Neuregulin-Hydrogel Therapy Reduces Scar Size and Enhances Post-Infarct Ventricular Contractility in an Ovine Large Animal Model

Jeffrey E Cohen  1 , Andrew B Goldstone  1 , Hanjay Wang  1 , Brendan P Purcell  2 , Yasuhiro Shudo  1 , John W MacArthur  1 , Amanda N Steele  1   3 , Michael J Paulsen  1 , Bryan B Edwards  1 , Chiaka N Aribeana  1 , Nicholas C Cheung  1 , Jason A Burdick  2 , Y Joseph Woo  1   3
Affiliations

A Bioengineered Neuregulin-Hydrogel Therapy Reduces Scar Size and Enhances Post-Infarct Ventricular Contractility in an Ovine Large Animal Model

Jeffrey E Cohen et al. J Cardiovasc Dev Dis. .

Abstract

The clinical efficacy of neuregulin (NRG) in the treatment of heart failure is hindered by off-target exposure due to systemic delivery. We previously encapsulated neuregulin in a hydrogel (HG) for targeted and sustained myocardial delivery, demonstrating significant induction of cardiomyocyte proliferation and preservation of post-infarct cardiac function in a murine myocardial infarction (MI) model. Here, we performed a focused evaluation of our hydrogel-encapsulated neuregulin (NRG-HG) therapy's potential to enhance cardiac function in an ovine large animal MI model. Adult male Dorset sheep (n = 21) underwent surgical induction of MI by coronary artery ligation. The sheep were randomized to receive an intramyocardial injection of saline, HG only, NRG only, or NRG-HG circumferentially around the infarct borderzone. Eight weeks after MI, closed-chest intracardiac pressure-volume hemodynamics were assessed, followed by heart explant for infarct size analysis. Compared to each of the control groups, NRG-HG significantly augmented left ventricular ejection fraction (p = 0.006) and contractility based on the slope of the end-systolic pressure-volume relationship (p = 0.006). NRG-HG also significantly reduced infarct scar size (p = 0.002). Overall, using a bioengineered hydrogel delivery system, a one-time dose of NRG delivered intramyocardially to the infarct borderzone at the time of MI in adult sheep significantly reduces scar size and enhances ventricular contractility at 8 weeks after MI.

Keywords: hydrogel; ischemic heart failure; myocardial infarction; neuregulin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Ovine myocardial infarction model using a mini left thoracotomy approach. (A) The left ventricle is exposed through a fifth interspace mini left thoracotomy incision. (B) Diagonal branches of the left anterior descending coronary artery are ligated using 5-0 or 6-0 polypropylene sutures (arrow), producing a consistently-sized pale and hypokinetic infarct zone (bounded by dotted line). The infarct borderzone lies immediately beyond the dotted yellow line.
Figure 2
Figure 2
Cardiac function at 8 weeks after myocardial infarction, measured by analyzing closed-chest left ventricular pressure-volume hemodynamics data. Data regarding (A) ejection fraction (%) and (B) the slope of the end-systolic pressure–volume relationship (ESPVR, mmHg/mL) are compared among sheep receiving saline (n = 6), hydrogel only (HG, n = 4), neuregulin only (NRG, n = 4), and hydrogel-encapsulated neuregulin (NRG-HG, n = 6). Data are presented as mean ± standard error. * indicates statistically significant (p < 0.05) compared to the NRG-HG group.
Figure 3
Figure 3
Representative pressure–volume loops for the (A) saline, (B) hydrogel only (HG), (C) neuregulin only (NRG), and (D) hydrogel-encapsulated neuregulin (NRG-HG) groups are shown. The slope of the end-systolic pressure-volume relationship (ESPVR, red line) is quantified.
Figure 4
Figure 4
Left ventricular endocardial scar size at 8 weeks after myocardial infarction. Representative photographs of sheep hearts from the (A) saline, (B) neuregulin only (NRG), and (C) hydrogel-encapsulated neuregulin (NRG-HG) groups are shown. (D) Quantified scar size for the saline (n = 6), hydrogel only (HG, n = 4), NRG only (n = 4), and NRG-HG groups (n = 7). Data are presented as mean ± standard error. ** indicates statistically significant (p < 0.01) compared to the NRG-HG group.
See this image and copyright information in PMC

References

    1. Virani S.S., Alonso A., Benjamin E.J., Bittencourt M.S., Callaway C.W., Carson A.P., Chamberlain A.M., Chang A.R., Cheng S., Delling F.N., et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020;141:e139–e596. doi: 10.1161/CIR.0000000000000757. - DOI - PubMed
    1. Heidenreich P.A., Trogdon J.G., Khavjou O.A., Butler J., Dracup K., Ezekowitz M.D., Finkelstein E.A., Hong Y., Johnston S.C., Khera A., et al. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation. 2011;123:933–944. doi: 10.1161/CIR.0b013e31820a55f5. - DOI - PubMed
    1. Ascheim D.D., Gelijns A.C., Goldstein D., Moye L.A., Smedira N., Lee S., Klodell C.T., Szady A., Parides M.K., Jeffries N.O., et al. Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation. 2014;129:2287–2296. doi: 10.1161/CIRCULATIONAHA.113.007412. - DOI - PMC - PubMed
    1. Menasché P. Cell therapy trials for heart regeneration—Lessons learned and future directions. Nat. Rev. Cardiol. 2018;15:659–671. doi: 10.1038/s41569-018-0013-0. - DOI - PubMed
    1. Luger D., Lipinski M.J., Westman P.C., Glover D.K., Dimastromatteo J., Frias J.C., Albelda M.T., Sikora S., Kharazi A., Vertelov G., et al. Intravenously Delivered Mesenchymal Stem Cells: Systemic Anti-Inflammatory Effects Improve Left Ventricular Dysfunction in Acute Myocardial Infarction and Ischemic Cardiomyopathy. Circ. Res. 2017;120:1598–1613. doi: 10.1161/CIRCRESAHA.117.310599. - DOI - PubMed

LinkOut - more resources